mirsaeed nikzad

In this work, 153Sm-zoledronate (153Sm-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy.
The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state using computational chemistry methods followed by 153Sm-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs.
The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. 153Sm-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.
The 153Sm-ZLD complex data were compared to 153Sm-EDTMP and 153Sm-BPAMD.

In this study, production, quality control and biodistribution studies of 166Ho-zoledronate have been presented as a possible bone marrow ablative agent. Ho-166 chloride was produced by thermal neutron irradiation of natural 165Ho(NO3)3 samples. 166Ho-zoledronate complex was prepared by adding the desired amount of zoledronate solution (0.2 mL, 150 mg/ml in 1 M NaOH) to appropriate amount of the 166HoCl3 solution. Radiochemical purity of the complex was monitored by instant thin layer chromatography (ITLC). Stability studies of the complex in the final preparation and in the presence of human serum were performed up to 48 h. The biodistribution of 166Ho-zoledronate and 166HoCl3 in wild-type mice was checked up to 72 h. 166Ho-zoledronate complex was prepared in high radiochemical purity (> 99%, ITLC) and specific activity of 4.4 GBq/mmol. The major accumulation of radiolabelled complex was observed in the bone tissue. These findings suggest 166Ho-zoledronatehas can be a possible candidate for bone marrow ablation in patients with multiple myeloma.